Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GBR 1302 in HER2 positive cancers
NCT02829372Phase 1Terminated
- Sponsor
- Ichnos Sciences Inc.
- Start
- May 2016
- Primary completion
- May 2019
- Modality
- Bispecific Antibodies, T-cell Engagers
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of GBR 1302 in solid tumor, sponsored by Ichnos Sciences Inc. Primary endpoints: Maximum Tolerated Dose at 28 days and Adverse Events at 28 days. Started May 2016; status: terminated.
02
Drugs
GBR 1302
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02829372.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02829372.